Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) posted Q4 FY26 revenue of Rs14,611.8cr and net profit Rs2,723.7cr, drove FY26 revenue Rs58,462.0cr with low leverage, won ANVISA clearance for once-weekly semaglutide in Brazil via Hypera, and secured Organon shareholder approval as the acquisition targets close in early 2027.
Previous Week Recap
- Sunpharma Q4 FY26 Revenue Rs14,611.8cr; Net Rs2,723.7cr: SUNPHARMA Q4 FY26 revenue Rs14,611.8cr, net profit Rs2,723.7cr versus Rs12,958.8cr and Rs2,160.6cr a year earlier. FY26 revenue Rs58,462.0cr, net Rs11,564.5cr; debt/equity 0.05
- Organon Shareholders Approve Acquisition; Close 2027: Sun Pharma says Organon shareholders approved its acquisition; deal still set to close in early 2027 (targeting Q4 FY27), pending remaining approvals and closing conditions.
- ANVISA OK For Semaglutide Pens Brazil: Sun Pharma got ANVISA approval to sell once-weekly semaglutide pens in Brazil (2 mg and 4 mg). Launch via Hypera partnership; company will supply API and formulations, partner supplies devices.
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.